ArticleBMC nephrology2026
Polymyxin B-associated hearing impairment in a patient with renal dysfunction- a case report.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPolymyxin B (PMB) is a polypeptide antibiotic primarily used to treat infections caused by multidrug-resistant gram-negative bacteria. Its main adverse effects are neurotoxicity and nephrotoxicity. Neurotoxicity may manifest as irritability, fatigue, lethargy, ataxia, dysgeusia, limb numbness, and blurred vision. Hearing impairment attributed to PMB is rarely reported. Herein, we describe a case of hearing impairment in a patient with renal dysfunction, potentially related to intravenous PMB therapy. CASE PRESENTATION: A 54-year-old, 70-kg male with poorly controlled type 2 diabetes (complicated by nephropathy, neuropathy, retinopathy), end-stage kidney disease (on hemodialysis), and hypertension was admitted to the ICU for gastrointestinal bleeding and hemorrhagic shock. On postoperative day 7, he developed carbapenem-resistant Acinetobacter baumannii (CR-AB) pneumonia and was treated with PMB 50 mg q12h plus sulbactam 2 g q8h. Therapeutic drug monitoring (TDM) showed the area under the plasma concentration-time curve across 24 h at steady state (AUC
conclusionsThis case highlights the importance of recognizing neurotoxic events related to PMB, including hearing impairment. Close monitoring and timely intervention are especially critical in patients with renal insufficiency or those receiving high-dose PMB. Accordingly, TDM plays an important role in anticipating and avoiding such adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.